The Medical Care Act was promulgated and implemented. The Dept. of Pharmaceutical Affairs was responsible for IND review.

Taiwan Cooperative Oncology Group (TCOG) was established.

Announcement No. 8246232 of the Ministry of Health and Welfare, July 7, 1993 (referred to as the "July 7 Announcement") was announced. Domestic clinical trial report must be included in NDA application.

Announcement of the Guidance for Industry: Good Clinical Practice (GCP).

Joint Institutional Review Board (JIRB) was established.

Implementation of Taiwan GCP.

Center for Drug Evaluation(CDE), Taiwan was established.

The Department of Health began to encourage and support the establishment of general clinical research centers (GCRC) to coordinate the management of clinical trials throughout the hospital.

Announcement No.0890035812 of the Ministry of Health and Welfare, Dec 12, 2000 (referred to as the "Dec 12 Announcement) was announced. Bridging Study Evaluation mechanism was developed.

IRB guidelines and accreditation were founded.

Announcement of the Regulations for Good Clinical Practice.

The Department of Health began to guide the domestic clinical trials to achieve higher study quality and standards by implementing the "Establish Outstanding Clinical Trial and Research System Program".

Taiwan Drug Clinical Trial Information platform was established.

Announcement of Regulations on Human Trials.

Taiwan Food and Drug Administration (TFDA) was established.

Announcement of Clinical Trial Notification (CTN).

Announcement of Human Subjects Research Act.

The establishment of the c-IRB Mechanism. The review process includes 20 days guaranteed main review and 10 days guaranteed sub review.

The Department of Health was upgraded to the Ministry of Health and Welfare.

Taiwan Clinical Trials was established.